Cargando…

Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk

BACKGROUND: The aim of the study was to investigate long-term risk and spectrum of subsequent neoplasm (SN) in childhood cancer survivors and to identify how trends in therapy influenced cumulative incidence of SN. PATIENTS AND METHODS: The population-based cohort comprises 3271 childhood cancer pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesen Mazic, Maja, Reulen, Raoul C., Jazbec, Janez, Zadravec Zaletel, Lorna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400439/
https://www.ncbi.nlm.nih.gov/pubmed/35848608
http://dx.doi.org/10.2478/raon-2022-0027
_version_ 1784772742416957440
author Cesen Mazic, Maja
Reulen, Raoul C.
Jazbec, Janez
Zadravec Zaletel, Lorna
author_facet Cesen Mazic, Maja
Reulen, Raoul C.
Jazbec, Janez
Zadravec Zaletel, Lorna
author_sort Cesen Mazic, Maja
collection PubMed
description BACKGROUND: The aim of the study was to investigate long-term risk and spectrum of subsequent neoplasm (SN) in childhood cancer survivors and to identify how trends in therapy influenced cumulative incidence of SN. PATIENTS AND METHODS: The population-based cohort comprises 3271 childhood cancer patients diagnosed in Slovenia aged ≤ 18 years between 1st January 1961 and 31st December 2013 with a follow-up through 31st December 2018. Main outcome measures are standardised incidence ratios (SIRs), absolute excess risks (AERs), and cumulative incidence of SN. RESULTS: After median follow-up time of 21.5 years for 5-year survivors, 230 patients experienced 273 SN, including 183 subsequent malignant neoplasm (SMN), 34 meningiomas and 56 nonmelanoma skin cancers. 10.5% patients received radiotherapy only, 31% chemotherapy only, 26.9% a combination of chemotherapy and radiotherapy and 16.1% surgery only. The overall SIR was almost 3 times more than expected (SIR 2.9), with survivors still at 2-fold increased risk after attained age 50 years. The observed cumulative incidence of SMN at 30-year after diagnosis was significantly lower for those diagnosed in 1960s, compared with the 1970s and the 1980s (P heterogeneity < 0.001). Despite reduced use of radiotherapy over time, the difference in cumulative incidence for the first 15 years after diagnosis was not significant for patients treated before or after 1995 (p = 0.11). CONCLUSIONS: Risks of developing a SMN in this study are similar to other European population-based cohorts. The intensity of treatment peaked later and use of radiotherapy declined slower compared to high income countries, making continuous surveillance even more important in the future.
format Online
Article
Text
id pubmed-9400439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-94004392022-09-07 Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk Cesen Mazic, Maja Reulen, Raoul C. Jazbec, Janez Zadravec Zaletel, Lorna Radiol Oncol Research Article BACKGROUND: The aim of the study was to investigate long-term risk and spectrum of subsequent neoplasm (SN) in childhood cancer survivors and to identify how trends in therapy influenced cumulative incidence of SN. PATIENTS AND METHODS: The population-based cohort comprises 3271 childhood cancer patients diagnosed in Slovenia aged ≤ 18 years between 1st January 1961 and 31st December 2013 with a follow-up through 31st December 2018. Main outcome measures are standardised incidence ratios (SIRs), absolute excess risks (AERs), and cumulative incidence of SN. RESULTS: After median follow-up time of 21.5 years for 5-year survivors, 230 patients experienced 273 SN, including 183 subsequent malignant neoplasm (SMN), 34 meningiomas and 56 nonmelanoma skin cancers. 10.5% patients received radiotherapy only, 31% chemotherapy only, 26.9% a combination of chemotherapy and radiotherapy and 16.1% surgery only. The overall SIR was almost 3 times more than expected (SIR 2.9), with survivors still at 2-fold increased risk after attained age 50 years. The observed cumulative incidence of SMN at 30-year after diagnosis was significantly lower for those diagnosed in 1960s, compared with the 1970s and the 1980s (P heterogeneity < 0.001). Despite reduced use of radiotherapy over time, the difference in cumulative incidence for the first 15 years after diagnosis was not significant for patients treated before or after 1995 (p = 0.11). CONCLUSIONS: Risks of developing a SMN in this study are similar to other European population-based cohorts. The intensity of treatment peaked later and use of radiotherapy declined slower compared to high income countries, making continuous surveillance even more important in the future. Sciendo 2022-08-14 /pmc/articles/PMC9400439/ /pubmed/35848608 http://dx.doi.org/10.2478/raon-2022-0027 Text en © 2022 Maja Cesen Mazic, Raoul C. Reulen, Janez Jazbec, Lorna Zadravec Zaletel, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
Cesen Mazic, Maja
Reulen, Raoul C.
Jazbec, Janez
Zadravec Zaletel, Lorna
Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title_full Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title_fullStr Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title_full_unstemmed Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title_short Trends in Treatment of Childhood Cancer and Subsequent Primary Neoplasm Risk
title_sort trends in treatment of childhood cancer and subsequent primary neoplasm risk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400439/
https://www.ncbi.nlm.nih.gov/pubmed/35848608
http://dx.doi.org/10.2478/raon-2022-0027
work_keys_str_mv AT cesenmazicmaja trendsintreatmentofchildhoodcancerandsubsequentprimaryneoplasmrisk
AT reulenraoulc trendsintreatmentofchildhoodcancerandsubsequentprimaryneoplasmrisk
AT jazbecjanez trendsintreatmentofchildhoodcancerandsubsequentprimaryneoplasmrisk
AT zadraveczaletellorna trendsintreatmentofchildhoodcancerandsubsequentprimaryneoplasmrisk